Cohort 1 | Cohort 2 | |||
---|---|---|---|---|
Controls | Patients with AD | Controls | Patients with AD | |
n | 28 | 36 | 20 | 70 |
Gender (male:female) | 13:15 | 15:21 | 14:6 | 29:41 |
Age (years) (mean ± SD) | 60 ± 7 | 62 ± 6 | 62 ± 3 | 62 ± 5 |
MMSE (mean ± SD) | 27 ± 3 | 19 ± 5*** | 28 ± 2 | 20 ± 6*** |
Aβ42 (pg/ml) (median [IQR]) | 915 [815–1026] | 468 [395–552]*** | 1063 [1009–1214] | 578 [518–645]*** |
tTau (pg/ml) (median [IQR]) | 216 [161–309] | 691 [559–962]*** | 274 [239–315] | 734 [552–1021]*** |
pTau (pg/ml) (median [IQR]) | 47 [33–54] | 92 [77–116]*** | 43 [39–50] | 90 [69–107]*** |
Contactin-2 (ng/ml) (median [IQR]) | 78 [69–110] | 59 [42–74]*** | 65 [54–99] | 61 [39–78]* |